Shoutaro Tsuji
Overview
Explore the profile of Shoutaro Tsuji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kouro T, Higashijima N, Horaguchi S, Mano Y, Kasajima R, Xiang H, et al.
Int J Cancer
. 2024 Jan;
154(10):1828-1841.
PMID: 38212893
The selection of highly specific target antigens is critical for the development of clinically efficient and safe chimeric antigen receptors (CARs). In search of diagnostic marker for malignant mesothelioma (MM),...
2.
Tamargo I, In Baek K, Xu C, Kang D, Kim Y, Andueza A, et al.
Circulation
. 2023 Dec;
149(15):1183-1201.
PMID: 38099436
Background: Atherosclerosis preferentially occurs in arterial regions of disturbed blood flow, and stable flow (s-flow) protects against atherosclerosis by incompletely understood mechanisms. Methods: Our single-cell RNA-sequencing data using the mouse...
3.
Mori K, Matsumoto K, Ikeda M, Koguchi D, Shimizu Y, Tsumura H, et al.
Diagnostics (Basel)
. 2023 Oct;
13(19).
PMID: 37835810
Objective: To investigate the correlation between total protein expression of heart development protein with EGF-like domain 1 (HEG1) and clinicopathological characteristics in patients with bladder cancer (BC) after radical cystectomy...
4.
Tsuji S, Imai K
Proc Jpn Acad Ser B Phys Biol Sci
. 2023 Feb;
99(2):39-47.
PMID: 36775341
Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleural cavity. Pathologically distinguishing MPM from other pleural lesions is often difficult. We searched for marker antigens to facilitate the...
5.
Hiroshima K, Wu D, Koh E, Sekine Y, Ozaki D, Yusa T, et al.
Pathol Int
. 2021 Jul;
71(9):604-613.
PMID: 34240508
Sialylated HEG1 has been reported as a highly specific and sensitive mesothelioma marker but a comprehensive evaluation of its expression in carcinomas in different organs, various sarcomas and reactive mesothelial...
6.
Moriwaki Y, Kubo N, Watanabe M, Asano S, Shinoda T, Sugino T, et al.
Sci Rep
. 2020 Jul;
10(1):11996.
PMID: 32686737
α7 nicotinic acetylcholine receptors (nAChRs) are widely expressed in the central nervous system and regarded as potential therapeutic targets for neurodegenerative conditions, such as Alzheimer's disease and schizophrenia. Yet, despite...
7.
Hiroshima K, Wu D, Hamakawa S, Tsuruoka S, Ozaki D, Orikasa H, et al.
Diagn Cytopathol
. 2020 May;
49(5):622-632.
PMID: 32441895
Background: The specificity and sensitivity of HEG1 for malignant mesothelioma (MM) is high. The use of BAP1/MTAP immunohistochemistry (IHC) is recommended to separate benign and malignant mesothelial proliferations. We determined...
8.
Fujii T, Itami H, Uchiyama T, Morita K, Nakai T, Hatakeyama K, et al.
Biochem Biophys Res Commun
. 2020 Apr;
526(4):927-933.
PMID: 32284171
Malignant mesothelioma (MM) is a fatal tumor, and the absence of a specific diagnostic marker and/or a pathogenic molecule-targeting drug is a major issue for its pathological diagnosis and for...
9.
Naso J, Tsuji S, Churg A
Am J Surg Pathol
. 2020 Mar;
44(8):1143-1148.
PMID: 32205484
Malignant mesothelioma can be difficult to distinguish from other malignancies, particularly non-small cell lung carcinomas (NSCLCs), without immunohistochemistry. However, conventional markers of mesothelial lineage all have variable degrees of cross-reactivity...
10.
Matsuura R, Kaji H, Tomioka A, Sato T, Narimatsu H, Moriwaki Y, et al.
Sci Rep
. 2018 Sep;
8(1):14251.
PMID: 30250045
The anti-mesothelioma mAb SKM9-2 recognizes the sialylated protein HEG homolog 1 (HEG1). HEG1 is a 400 kDa mucin-like membrane protein found on mesothelioma. SKM9-2 can detect mesothelioma more specifically and...